Kyle Dempsey
Director/Board Member at OPTINOSE, INC.
Net worth: 6 089 $ as of 30/04/2024
Kyle Dempsey active positions
| Companies | Position | Start | End |
|---|---|---|---|
| OPTINOSE, INC. | Director/Board Member | 10/12/2021 | - |
| Independent Dir/Board Member | 10/12/2021 | - | |
| HLS THERAPEUTICS INC. | Director/Board Member | 29/11/2022 | - |
| Independent Dir/Board Member | 29/11/2022 | - | |
| MVM Partners LLC | Private Equity Investor | 01/09/2017 | - |
GT Medical Technologies, Inc.
 GT Medical Technologies, Inc. Medical SpecialtiesHealth Technology GT Medical Technologies, Inc. engages in the design and development of a medical device for the treatment of brain tumors. It offers GammaTile Therapy, which is a surgically targeted radiation therapy which is placed at the end if a brain excision surgery and targets residual tumor cells. The company was founded by Heyoung McBride, Peter Nakaji, Emad Youssef, and Theresa Thomas in 2017 and is headquartered in Tempe, AZ. | Director/Board Member | - | - |
Career history of Kyle Dempsey
Training of Kyle Dempsey
| Harvard Medical School | Doctorate Degree |
| Bowdoin College | Undergraduate Degree |
| Harvard Business School | Masters Business Admin |
Statistics
International
| United States | 7 |
| Canada | 2 |
Operational
| Director/Board Member | 3 |
| Independent Dir/Board Member | 2 |
| Private Equity Investor | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 4 |
| Finance | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| OPTINOSE, INC. | Health Technology |
| HLS THERAPEUTICS INC. | Health Technology |
| Private companies | 2 |
|---|---|
| MVM Partners LLC | Finance |
GT Medical Technologies, Inc.
GT Medical Technologies, Inc. Medical SpecialtiesHealth Technology GT Medical Technologies, Inc. engages in the design and development of a medical device for the treatment of brain tumors. It offers GammaTile Therapy, which is a surgically targeted radiation therapy which is placed at the end if a brain excision surgery and targets residual tumor cells. The company was founded by Heyoung McBride, Peter Nakaji, Emad Youssef, and Theresa Thomas in 2017 and is headquartered in Tempe, AZ. | Health Technology |
- Stock Market
- Insiders
- Kyle Dempsey
- Experience
